Spero Therapeutics announces clearance by U.S. FDA of IND for SPR206

Spero Therapeutics announced that it has received clearance by the U.S. Food and Drug Administration, FDA, for its investigational new drug, IND, application, to evaluate SPR206 in a Phase 2 clinical study. “Clearance of this IND is an important milestone in our SPR206 development program, as we prepare to advance this drug candidate into a Phase 2 trial in HABP/VABP,” said Kamal Hamed, Spero’s Chief Medical Officer. “HABP/VABP are serious infections associated with high mortality and substantial morbidity, and their management has been complicated by the increasing prevalence of difficult-to-treat and MDR Gram-negative pathogens. SPR206 is being developed to address this unmet need, and if approved, we believe it could provide clinicians with a valuable new therapeutic option.”